US-based medical device firm SentreHeart has completed patient enrolment in stage I of its aMAZE trial for LARIAT Suture Delivery System (LARIAT).

The aMAZE trial evaluates the outcomes of LARIAT in closure of left atrial appendage in combination with pulmonary vein isolation catheter ablation, in patients with drug-refractory, persistent and long-standing persistent AFib.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Stage I of the trial examines the safety and performance of the LARIAT procedure in the first 100 consecutively enrolled subjects.

"The rapid completion of this significant enrolment milestone demonstrates that clinicians and patients are seeking new therapeutic options for the treatment of persistent and long-standing persistent AFib."

With the first subject enrolled in October 2015, the firm is currently enlisting subjects at 34 US centres, with plans to expand to 50 centres.

SentreHeart chief executive officer and president Russ Seiber said: “We are delighted by the enrolment progress of the aMAZE Trial and are excited have achieved our 2016 enrollment objectives.

“The rapid completion of this significant enrolment milestone demonstrates that clinicians and patients are seeking new therapeutic options for the treatment of persistent and long-standing persistent AFib.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

AFib is an irregular, rapid heartbeat of the heart's atria caused due to a malfunction in the organ's electrical system.

The studies conducted indicate that LARIAT closes the LAA mechanically as well as isolates electrical activity within the LAA, which can be used to treat patients with persistent or longstanding persistent AFib.

The LARIAT can remove LAA as a source of AFib and nidus for thrombus.

In the trial, the percutaneous, non-implant LARIAT suture delivery device is used to treat AF by mechanically and electrically isolating the base of the LAA

SentreHeart intends to enroll a total of approximately 600 patients for the aMAZA trial.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact